INTRO-TB-VAX

Investigating a Novel Targeted ROllout strategy for adult and adolescent TB Vaccines for mAXimum impact

Information

A Mixed-methods implementation study that assesses specific locations that have the potential to make a significant impact on the introduction of the new TB vaccine for adults and adolescents. This study includes an IGRA Prevalence Study, as well as a Health System Readiness Assessment to evaluate the readiness of health facilities for TB vaccination. This study will provide a holistic approach to understand the factors that influence uptake, informing strategies to maximize acceptance of new vaccines.

Gates Foundation (sponsor)
UCSF (Collaborator)
JHU (Collaborator)
UBC (IGRA Kit Distributor)
Lab Biomedis Unpad (Central Lab)
Lab Terpadu FKUI (Central Lab)

Type of Study

Stakeholders Involved

Mixed Method Implementation Study

Background

Despite many notable advancements over the last decade, tuberculosis (TB) remains a persistent global health challenge with 10 million new cases and 1.5 million deaths annually. This shows the need for the rollout and scale-up of an effective and safe TB vaccine for adults and adolescents. With several vaccine trials still on going, however, a significant gap remains in our preparedness for their real-world implementation. One key challenge is different vaccine mechanisms with efficacy tied to individuals’ TB infection (TBI) status. Furthermore, understanding the most preferred, feasible, impactful, and cost-effective implementation strategies to reach adults and adolescents in high TB burden communities with a new TB vaccine will be essential for optimizing their impact.